首页 > 市场调查报告书 > 医疗设备

体外诊断癌症癌症诊断

市场调查报告书

商品编码

1628131

癌症诊断市场机会、成长动力、产业趋势分析与预测 2025 - 2034

Cancer Diagnostics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

出版日期: 2024年11月22日 | 出版商:

Global Market Insights Inc. | 英文 135 Pages | 商品交期: 2-3个工作天内

价格

简介目录

全球癌症诊断市场到 2024 年价值为 1587 亿美元，预计 2025 年至 2034 年间将以 9% 的复合年增长率稳定增长。主要目的是确定癌症的类型、位置和进展，以便及时有效的治疗，从而改善患者的治疗结果。

市场扩张主要是由全球癌症盛行率不断上升所推动的。预测显示癌症病例数量急剧增加，强调了对先进诊断方法的迫切需求。这种日益增加的负担正在推动成像和分子诊断等技术的采用，这些技术在早期检测和准确诊断中发挥着至关重要的作用。

医疗保健系统的技术进步，特别是在发展中地区，正在进一步推动市场成长。对医疗保健基础设施的投资和包括远距医疗在内的尖端工具的引入，使癌症诊断变得更加容易和高效。这些创新支持更快、更精确的检测，改善整体患者护理。

市场范围
开始年份	2024年
预测年份	2025-2034
起始值	1,587 亿美元
预测值	3,725 亿美元
复合年增长率	9%

市场按应用细分为肿瘤生物标记测试、影像、活检、液体活检、免疫组织化学和原位杂交。影像占据最大的收入份额，到 2024 年将占 63.6%。

根据癌症类型，市场分为几个部分，包括膀胱癌、乳腺癌、大肠癌、子宫内膜癌、肾癌、肝癌、肺癌和前列腺癌。 2024 年，肝癌和肺癌合计占市场份额的 18.4%，预计到 2034 年将出现强劲增长。环境触发因素和不健康的生活习惯等因素正在推动这些癌症的发病率增加，凸显了有效诊断的迫切需要解决方案。

最终用户部分包括医院、诊断实验室、影像中心和癌症研究机构。医院由于广泛采用先进的诊断设备和熟练的医疗保健专业人员而在这一类别中占据主导地位。有利的报销政策进一步支持细分市场的成长，确保获得高品质的诊断服务。

从地区来看，美国预计将经历显着的市场扩张，预计到 2034 年市场规模将达到 1350 亿美元。

产业生态系统分析
产业影响力
- 成长动力
  - 全球癌症盛行率上升
  - 政府和其他组织为传播疾病意识而采取的多项倡议
  - 发展中国家的诊断实验室数量不断增加
  - 已开发国家的技术进步
- 产业陷阱与挑战
  - 高资本投资以及与诊断影像系统相关的高成本
  - 与影响 CT 扫描仪使用的高辐射暴露相关的风险
成长潜力分析
监管环境
技术景观
- 核心技术
- 邻近技术
未来市场趋势
差距分析
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
公司市占率分析
公司矩阵分析
主要市场参与者的竞争分析
竞争定位矩阵
战略仪表板

第 5 章：市场估计与预测：按应用分类，2021 - 2034 年

主要趋势
肿瘤生物标记测试
影像学
- 超音波和放射学
- 乳房X光检查
- 核磁共振扫描
- 正子断层扫描
- CT扫描
- SPECT 和其他影像
活检
液体活检
免疫组织化学
原位杂交

第 6 章：市场估计与预测：按癌症类型，2021 - 2034 年

主要趋势
膀胱癌
乳癌
结肠癌和直肠癌
子宫内膜癌
肾癌
白血病
肝癌和肺癌
黑色素瘤
非何杰金氏淋巴瘤
胰腺癌
摄护腺癌
甲状腺癌
其他癌症类型

第 7 章：市场估计与预测：按最终用途，2021 - 2034 年

主要趋势
医院
诊断实验室
诊断影像中心
癌症研究机构

第 8 章：市场估计与预测：按地区，2021 - 2034

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 俄罗斯
亚太地区
- 中国
- 日本
- 印度
- 澳洲
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋

第 9 章：公司简介

Abbott Laboratories
AB Sciex Pte
Agilent Technologies
Becton, Dickinson and Company
Biocare Medical
Biocartis
Biomerieux
Bio-Rad Laboratories
Danaher Corporation
F-Hoffmann-La Roche
GE Healthcare
Hologic
Johnson & Johnson
Koninklijke Philips
Myriad Genetics
QIAGEN
Siemens Healthineers
Sysmex Corporation
Thermo Fisher Scientific

简介目录

Product Code: 2406

The Global Cancer Diagnostics Market, valued at USD 158.7 billion in 2024, is poised for steady growth at a CAGR of 9% between 2025 and 2034. Cancer diagnostics encompasses a range of tests and technologies designed to detect and identify cancer at its earliest stages. The primary aim is to determine the type, location, and progression of cancer to enable timely and effective treatment, thereby improving patient outcomes.

The market expansion is primarily driven by the increasing global prevalence of cancer. Projections indicate a sharp rise in the number of cancer cases, emphasizing the critical need for advanced diagnostic methods. This growing burden is boosting the adoption of technologies such as imaging and molecular diagnostics, which play a crucial role in early detection and accurate diagnosis.

Technological advancements in healthcare systems, particularly in developing regions, are further propelling market growth. Investments in healthcare infrastructure and the introduction of cutting-edge tools, including telemedicine, have made cancer diagnostics more accessible and efficient. These innovations support faster and more precise detection, improving overall patient care.

Market Scope
Start Year	2024
Forecast Year	2025-2034
Start Value	$158.7 Billion
Forecast Value	$372.5 Billion
CAGR	9%

The market is segmented by application into tumor biomarker tests, imaging, biopsy, liquid biopsy, immunohistochemistry, and in situ hybridization. Imaging accounts for the largest revenue share, capturing 63.6% in 2024. Increasing awareness about breast cancer screenings and developing advanced imaging technologies are key contributors to this segment's dominance.

By cancer type, the market is categorized into several segments, including bladder, breast, colorectal, endometrial, kidney, liver, lung, and prostate cancer. Liver and lung cancers together accounted for 18.4% of the market share in 2024 and are expected to see robust growth through 2034. Factors such as environmental triggers and unhealthy lifestyle habits are driving the increased incidence of these cancers, highlighting the urgent need for effective diagnostic solutions.

End-user segments include hospitals, diagnostic laboratories, imaging centers, and cancer research institutes. Hospitals dominate this category due to their widespread adoption of advanced diagnostic equipment and the presence of skilled healthcare professionals. Favorable reimbursement policies further support segment growth, ensuring access to high-quality diagnostic services.

Regionally, the U.S. is expected to experience significant market expansion, with projections estimating the market size to reach USD 135 billion by 2034. Factors like an aging population and increased demand for advanced diagnostic tools contribute to the growth in this region.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising prevalence of cancer globally
  - 3.2.1.2 Several initiatives undertaken by government and other organizations to spread disease awareness
  - 3.2.1.3 Growing number of diagnostic laboratories in developing countries
  - 3.2.1.4 Technology advancements in developed countries
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High capital investment coupled with high costs associated with diagnostic imaging systems
  - 3.2.2.2 Risk related with high radiation exposure affecting use of CT scanner
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
- 3.5.1 Core technologies
- 3.5.2 Adjacent technologies
3.6 Future market trends
3.7 Gap analysis
3.8 Porter's analysis
3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

5.1 Key trends
5.2 Tumor biomarkers tests
5.3 Imaging
- 5.3.1 Ultrasound and radiology
- 5.3.2 Mammography
- 5.3.3 MRI scan
- 5.3.4 PET scan
- 5.3.5 CT scan
- 5.3.6 SPECT and other imaging
5.4 Biopsy
5.5 Liquid biopsy
5.6 Immunohistochemistry
5.7 In situ hybridization

Chapter 6 Market Estimates and Forecast, By Cancer Type, 2021 - 2034 ($ Mn)

6.1 Key trends
6.2 Bladder cancer
6.3 Breast cancer
6.4 Colon and rectal cancer
6.5 Endometrial cancer
6.6 Kidney cancer
6.7 Leukemia
6.8 Liver and lung cancer
6.9 Melanoma
6.10 Non-hodgkin lymphoma
6.11 Pancreatic cancer
6.12 Prostate cancer
6.13 Thyroid cancer
6.14 Other cancer types

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

7.1 Key trends
7.2 Hospitals
7.3 Diagnostic laboratories
7.4 Diagnostic imaging centers
7.5 Cancer research institutes

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Russia
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE